Imugene Ltd
ASX:IMU
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.25
1.53
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
There is not enough data to reliably calculate the intrinsic value of IMU.
The Intrinsic Value is calculated as the average of DCF and Relative values:
| FR |
|
Pharnext SCA
OTC:PNEXF
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Substantial clinical risk remains with Imugene’s CF33-based oncolytic virus platform, as disappointing trial results for even one major candidate could undermine investor confidence and derail the company’s broader immuno-oncology pipeline.
Heavily reliant on equity issuance and government grants for funding, Imugene may face significant dilution to existing shareholders if clinical timelines stretch and further capital is needed to support late-stage studies.
Growing competition in the immuno-oncology space, particularly from larger pharmaceutical players with far greater resources, could overshadow Imugene’s pipeline and limit licensing or commercialization prospects.
Imugene’s multivalent approach to immuno-oncology, highlighted by its CF33 oncolytic virus and HER-Vaxx candidates, offers significant potential breakthroughs in treating various tumor types, positioning the firm as a future leader in next-generation cancer therapies.
Early clinical data has shown promising efficacy and safety signals, which could attract additional partnerships or licensing deals with big pharma and expedite the development timeline for lead candidates.
Imugene’s expanding intellectual property portfolio and strategic focus on novel checkpoint inhibitors and therapeutic vaccines provide strong competitive barriers and could create long-term shareholder value if the pipeline succeeds.
Revenue & Expenses Breakdown
Imugene Ltd
Balance Sheet Decomposition
Imugene Ltd
| Current Assets | 41.7m |
| Cash & Short-Term Investments | 24m |
| Receivables | 10m |
| Other Current Assets | 7.7m |
| Non-Current Assets | 41.8m |
| Long-Term Investments | 224.9k |
| PP&E | 1.7m |
| Intangibles | 31.7m |
| Other Non-Current Assets | 8.2m |
| Current Liabilities | 22.2m |
| Accounts Payable | 6.8m |
| Accrued Liabilities | 6.4m |
| Other Current Liabilities | 8.9m |
| Non-Current Liabilities | 16.4m |
| Long-Term Debt | 2.8m |
| Other Non-Current Liabilities | 13.6m |
Free Cash Flow Analysis
Imugene Ltd
| AUD | |
| Free Cash Flow | AUD |
Earnings Waterfall
Imugene Ltd
|
Revenue
|
0
AUD
|
|
Operating Expenses
|
-77.6m
AUD
|
|
Operating Income
|
-77.6m
AUD
|
|
Other Expenses
|
8.6m
AUD
|
|
Net Income
|
-69m
AUD
|
IMU Profitability Score
Profitability Due Diligence
Imugene Ltd's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Imugene Ltd's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
IMU Solvency Score
Solvency Due Diligence
Imugene Ltd's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Score
Imugene Ltd's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IMU Price Targets Summary
Imugene Ltd
Dividends
Current shareholder yield for
IMU is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?